Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Richard Shubin

Neurology Arcadia, CA Medical Doctor

NPI 1265442180 CMS profile 147520

1015 North First Ave, Suite A, Arcadia, CA 91006

Open in the dashboard

General payments

$189,041

720 records reported · program years 2019–2024

Research payments

$2,265

Paid to them · 6 records reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,779,924 paid to institutions, not to them · program years 2019–2023

Through program year 2024, Richard Shubin of Arcadia, CA is reported in the CMS Open Payments database as having received $189,041 across 720 general payments and $2,265 in research payments paid to them. Separately, studies naming them as principal investigator received $1,779,924 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $15 1
2023 General $15 1
2023 Research $200 1
2022 Research $450 1
2021 General $36,561 139
2021 Research $677 1
2020 General $61,308 257
2019 General $91,142 322
2019 Research $939 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Richard Shubin
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Richard Shubin were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Richard Shubin Neurology median Middle half National median
2019 $91,142 $474 $118–$2,177 $163
2020 $61,308 $367 $82–$2,309 $114
2021 $36,561 $438 $104–$2,547 $132
2022 $0 $442 $103–$2,388 $149
2023 $15 $464 $119–$2,312 $160
2024 $15 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Novartis Pharmaceuticals Corporation $46,255 121 payments
  2. Genzyme Corporation $37,829 85 payments
  3. Biogen, Inc. $34,626 63 payments
  4. Teva Pharmaceuticals USA, Inc. $15,489 61 payments
  5. Genentech USA, Inc. $10,815 24 payments
  6. Celgene Corporation $10,108 14 payments
  7. Janssen Pharmaceuticals, Inc $7,636 10 payments
  8. Amneal Pharmaceuticals LLC $7,292 18 payments
  9. Allergan Inc. $7,096 13 payments
  10. UCB, Inc. $2,978 38 payments
  11. Other $8,916 273 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $131,184 71 payments
  2. Consulting Fee $28,573 15 payments
  3. Food and Beverage $12,861 565 payments
  4. Travel and Lodging $8,884 49 payments
  5. Honoraria $7,103 8 payments
  6. Education $437 12 payments
Products named General payments · program years 2019–2024
  1. GILENYA $19,355 20 payments
  2. LEMTRADA $17,799 37 payments
  3. AUBAGIO $13,603 25 payments
  4. VUMERITY $12,402 20 payments
  5. MAYZENT $11,855 46 payments
  6. OCREVUS $10,790 23 payments
  7. ZEPOSIA $10,177 18 payments
  8. PLEGRIDY $9,476 6 payments
  9. Ajovy $8,486 22 payments
  10. RYTARY $7,292 18 payments
  11. Other $47,560 475 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. Eli Lilly and Company $2,165 4 payments
  2. EMD Serono, Inc. $100 2 payments

Records

726 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record